ELVN

Enliven Therapeutics Inc

• TipRanks·11h ago

  Enliven Therapeutics: Strengthening ELVN-001 Profile and M&A Optionality Support Buy Rating and $56 Price Target

• TipRanks·1d ago

  Leveraging Merck–Terns Benchmark: Supporting Enliven’s ELVN-001 Upside and a Raised $60 Buy Target

• TipRanks·2d ago

  JonesTrading Keeps Their Buy Rating on Enliven Therapeutics (ELVN)

• Seeking Alpha·03/30 18:10

  Tango Therapeutics is the best performing healthcare stock in March

• TipRanks·03/28 14:36

  LifeSci Capital Keeps Their Buy Rating on Enliven Therapeutics (ELVN)

• Reuters·03/27 20:58

  Enliven Therapeutics; Chief Medical Officer Helen Louise Collins disposes of 40,000 common shares valued at $1,404,024

• TipRanks·03/26 16:07

  Enliven rises 11.0%

• Dow Jones·03/26 12:56

  Enliven Therapeutics Price Target Raised to $56.00/Share From $48.00 by HC Wainwright & Co.

• Dow Jones·03/26 12:56

  Enliven Therapeutics Is Maintained at Buy by HC Wainwright & Co.

• Benzinga·03/26 12:55

  HC Wainwright & Co. Maintains Buy on Enliven Therapeutics, Raises Price Target to $56

• TipRanks·03/26 10:21

  Enliven price target raised to $56 from $48 at H.C. Wainwright

• Reuters·03/26 10:13

  ENLIVEN THERAPEUTICS, INC. <ELVN.O>: H.C. WAINWRIGHT RAISES TARGET PRICE TO $56 FROM $48

• Reuters·03/26 07:38

  U.S. RESEARCH ROUNDUP- Equitable Holdings, Robinhood Markets, Wingstop

• Reuters·03/25 15:49

  BUZZ-U.S. STOCKS ON THE MOVE-BWX, Generac, Cintas

• Dow Jones·03/25 14:41

  Enliven Therapeutics Price Target Raised to $45.00/Share From $41.00 by Mizuho